ImageneBio, Inc. (Nasdaq: IMA) entered into a definitive securities purchase agreement on April 13 2026 that will generate gross proceeds of approximately $30 million. The transaction involves the sale of pre‑funded warrants that allow investors to purchase up to 5,770,335 shares of common stock at a warrant price of $5.199, with an exercise price of $0.001 per share.
The company will deploy the proceeds to advance its lead OX40 antibody, IMG‑007, in alopecia areata and to fund late‑stage development activities in atopic dermatitis. The financing extends ImageneBio’s runway, enabling continued progress in the Phase 2b ADAPTIVE trial and accelerating the alopecia areata program, which the company views as a key opportunity to bring a differentiated, non‑depleting OX40 therapy to market.
The private placement is led by Coastlands Capital and includes participation from Trails Edge Capital Partners, Omega Funds, and OrbiMed, with Leerink Partners acting as placement agent. The transaction also grants registration rights to the investors, allowing them to register the shares for public sale after a specified period.
Prior to the raise, ImageneBio reported $135.3 million in cash at the end of 2025, following earlier financing and a merger that created the current corporate structure. At the time of the announcement, the company’s market capitalization was roughly $55 million. The stock had gained about 8 % over the preceding week but had declined roughly 71 % over the past year, underscoring the need for additional capital to support its clinical program.
Management highlighted the strategic importance of the funding. CEO Kristin Yarema said, "We believe IMG‑007, working upstream of other targets in the immune‑cascade, is strongly differentiated, with disease‑modifying potential." She added, "We are pleased with the progress of our Phase 2b ADAPTIVE trial in atopic dermatitis and excited to be moving forward as planned under our amended protocol." Yarema also noted that the investor support will allow the company to "advance our alopecia areata program, an indication where we have already seen promising clinical proof‑of‑concept with IMG‑007 and where there is great unmet need for a biologic with durable efficacy and a strong tolerability profile."
The $30 million raise positions ImageneBio to pursue critical milestones, including the release of topline data from the Phase 2b ADAPTIVE trial in Q4 2026. The funding also strengthens the company’s competitive stance in the OX40 space, where other candidates have faced setbacks, and supports the development of a therapy that could offer a unique mechanism of action and improved patient experience.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.